Calculation
P/BV | = | Share price1, 2, 3 | ÷ | Book value per share1 (BVPS) | BVPS1 | = | Equity (deficit) attributable to IQVIA Holdings Inc.’s stockholders1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
---|---|---|---|---|---|---|---|---|---|---|---|
Feb 15, 2023 | 7.31 | = | 227.03 | ÷ | 31.04 | 31.04 | = | 5,765 | ÷ | 185,722,621 | |
Feb 16, 2022 | 7.32 | = | 232.18 | ÷ | 31.72 | 31.72 | = | 6,042 | ÷ | 190,485,264 | |
Feb 12, 2021 | 6.14 | = | 192.66 | ÷ | 31.37 | 31.37 | = | 6,001 | ÷ | 191,281,286 | |
Feb 18, 2020 | 5.30 | = | 165.42 | ÷ | 31.21 | 31.21 | = | 6,003 | ÷ | 192,339,093 | |
Feb 19, 2019 | 4.16 | = | 141.49 | ÷ | 33.98 | 33.98 | = | 6,714 | ÷ | 197,599,861 | |
Feb 16, 2018 | 2.61 | = | 101.72 | ÷ | 38.94 | 38.94 | = | 8,109 | ÷ | 208,251,468 | |
Feb 16, 2017 | 2.10 | = | 76.87 | ÷ | 36.62 | 36.62 | = | 8,633 | ÷ | 235,719,111 | |
Feb 11, 2016 | — | = | 59.00 | ÷ | -4.73 | -4.73 | = | -564 | ÷ | 119,384,993 | |
Feb 12, 2015 | — | = | 63.25 | ÷ | -5.66 | -5.66 | = | -704 | ÷ | 124,315,113 | |
Feb 13, 2014 | — | = | 52.20 | ÷ | -5.14 | -5.14 | = | -667 | ÷ | 129,842,707 |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of IQVIA Holdings Inc. Annual Report.
- Share Price Trend
- The share price exhibited an overall upward trend from 2014 to 2023. Beginning at $52.20 in February 2014, it increased consistently year over year, reaching a peak of $232.18 in February 2022 before slightly declining to $227.03 in February 2023. This pattern indicates strong market confidence and growth in the company's valuation over the analyzed period.
- Book Value Per Share (BVPS) Trend
- The book value per share showed notable volatility. Initially, BVPS was negative from 2014 through 2016, with values of -$5.14, -$5.66, and -$4.73 respectively. A significant positive shift occurred in 2017, when BVPS jumped to $36.62, followed by a mild increase to $38.94 in 2018. Subsequently, a gradual decline was observed from 2018 through 2023, with BVPS decreasing to $31.04 by 2023. This shift from negative to positive BVPS indicates a major improvement in net asset value at that midpoint, despite some erosion in later years.
- Price-to-Book Value Ratio (P/BV) Trend
- The P/BV ratio data is available starting 2017 and shows a rising trend over the period. The ratio increased from 2.1 in 2017 to 7.31 in 2023. This consistent rise suggests that the market price grew at a faster rate than the book value per share, reflecting increasing investor willingness to pay a premium over the net asset value. The peak P/BV ratio of 7.32 in 2022 aligns with the peak share price that year.
- Overall Insights
- The data indicates strong equity market performance, with the share price steadily increasing. The transition from negative to positive BVPS marks a significant turnaround in the company's balance sheet strength during the observed period. The increasing P/BV ratio points to elevated market expectations and possibly improved profitability or growth prospects as perceived by investors. The slight decline in share price and stabilization of P/BV in the most recent year may warrant monitoring for potential market adjustments or changes in company fundamentals.
Comparison to Competitors
IQVIA Holdings Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Feb 15, 2023 | 7.31 | 15.52 | 35.01 | 4.88 | 3.64 | 29.36 | 4.90 | 5.37 | 6.07 | 2.48 | 3.77 | 4.83 | 5.50 |
Feb 16, 2022 | 7.32 | 16.53 | 18.51 | 4.07 | 4.16 | 25.28 | 3.65 | 5.90 | 5.05 | 3.35 | 3.60 | 5.18 | 6.16 |
Feb 12, 2021 | 6.14 | 14.18 | 14.53 | 3.55 | 3.93 | 35.07 | 4.33 | 6.72 | 7.46 | 2.98 | 4.81 | 5.15 | 6.30 |
Feb 18, 2020 | 5.30 | — | 13.84 | 2.80 | 3.72 | 51.67 | 3.93 | 6.61 | 7.83 | 3.00 | 3.79 | 4.16 | 10.23 |
Feb 19, 2019 | 4.16 | — | 9.41 | 5.89 | 2.80 | 12.87 | 3.89 | 6.08 | 7.79 | 3.80 | 5.07 | 3.75 | 10.68 |
Feb 16, 2018 | 2.61 | 36.95 | 5.02 | 8.88 | 2.58 | 7.33 | 5.15 | 5.79 | 4.30 | 2.94 | 5.66 | 3.30 | 20.14 |
Feb 16, 2017 | 2.10 | 21.24 | 4.14 | 5.66 | 2.56 | 6.33 | 4.88 | 4.72 | 4.51 | 3.40 | 8.58 | 2.86 | 18.42 |
Feb 11, 2016 | — | 22.17 | 3.94 | 7.04 | 2.53 | 5.51 | 6.59 | 4.07 | 3.15 | 2.84 | 10.53 | 2.42 | 22.38 |
Feb 12, 2015 | — | 56.09 | 4.59 | 6.72 | 2.63 | 5.14 | 10.08 | 4.01 | 3.42 | 2.95 | 16.22 | 2.51 | 25.60 |
Feb 13, 2014 | — | 18.05 | 4.30 | 5.92 | 2.38 | 3.69 | 11.36 | 3.50 | 3.35 | 2.69 | 16.74 | 2.90 | 14.77 |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
IQVIA Holdings Inc., P/BV, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
IQVIA Holdings Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
---|---|---|
Feb 15, 2023 | 7.31 | 5.66 |
Feb 16, 2022 | 7.32 | 5.72 |
Feb 12, 2021 | 6.14 | 5.99 |
Feb 18, 2020 | 5.30 | 5.82 |
Feb 19, 2019 | 4.16 | 6.02 |
Feb 16, 2018 | 2.61 | 5.14 |
Feb 16, 2017 | 2.10 | 4.58 |
Feb 11, 2016 | — | 4.15 |
Feb 12, 2015 | — | 4.47 |
Feb 13, 2014 | — | 3.97 |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).
Comparison to Industry (Health Care)
IQVIA Holdings Inc. | Health Care | |
---|---|---|
Feb 15, 2023 | 7.31 | 87,112.79 |
Feb 16, 2022 | 7.32 | 5.48 |
Feb 12, 2021 | 6.14 | 5.37 |
Feb 18, 2020 | 5.30 | 5.14 |
Feb 19, 2019 | 4.16 | 5.17 |
Feb 16, 2018 | 2.61 | 4.55 |
Feb 16, 2017 | 2.10 | 4.06 |
Feb 11, 2016 | — | 3.62 |
Feb 12, 2015 | — | 4.10 |
Feb 13, 2014 | — | 3.51 |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).